Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil, when applied to the scalp, can stimulate hair growth but effects vary, stop if treatment ends, and it may cause side effects like fluid retention.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

Potassium iodide prevents hair loss and reduces toxicity from thallium acetate.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study evaluated an herbal emulgel formulation containing extracts from Wedelia chinensis and Cassytha filiformis for hair growth promotion in rats, finding that the combined formulation significantly increased hair growth compared to both individual extracts and the control group.

The researchers reported that zinc carbonate nanoparticles stabilized with polyvinylpyrrolidone did not show local irritant or skin-resorptive effects in preclinical tests on rabbits and rats.

In this case report, a 28-year-old woman with alopecia areata experienced reduced hair fall and gradual hair regrowth following treatment with individualized homeopathy, but the authors note that further studies with larger patient groups are needed to confirm these findings.

This study found that human skin melanocytes with low mutation burdens are smaller, less dendritic, and exhibit stem-like features, often residing in UV-protected hair follicles, suggesting their role in replenishing sun-damaged epidermis.

This review discusses the various skin changes, pregnancy-specific dermatoses, and medication management related to dermatologic health during pregnancy, aiming to provide clinicians with an evidence-based guide for diagnosis and treatment.

This study identified distinct plasma miRNA profiles in alopecia areata that may aid in diagnosis and therapy, but further validation is needed to confirm these exploratory findings.

In this case study, a woman with congenital adrenal hyperplasia experienced substantial improvement in musculoskeletal and neurobehavioral symptoms after low-dose testosterone therapy, highlighting its potential role in managing chronic glucocorticoid overtreatment effects.

This study observed that 78.3% of patients with alopecia areata exhibited nail changes detectable by dermoscopy, notably nail pitting, in contrast to 14.2% of healthy controls, with these changes significantly associated with disease severity, age, and duration.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

In this case report, a 62-year-old woman with suspected discoid lupus erythematosus experienced worsening skin and hair symptoms despite treatment with topical corticosteroids, immunomodulatory therapy, and hydroxychloroquine, leading to her referral to a tertiary dermatology center.

This study found that in patients with Alopecia Areata, CD27 and IL-35 levels were significantly higher in those with bacterial infections, suggesting they may be useful as immunological biomarkers.

This study suggests that elevated levels of IL-17A and IL-23 in alopecia areata may play roles in disease severity and activity, providing insights into potential therapeutic targets.

In this case report, a 40-year-old woman with systemic lupus erythematosus developed calcinosis cutis, a rare complication characterized by calcified deposits in her legs, requiring surgical intervention and ongoing medical treatment due to infection.

In this study, GV-350 treatment over three months improved iron status and reduced the impact of Telogen Effluvium on quality of life among 20 iron-deficient women, with no adverse events reported.

In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.

This study developed the SAALIQ, a culturally adapted tool specifically for measuring quality of life in Spanish-speaking patients with alopecia areata, highlighting its strong psychometric performance and the benefit of capturing overlooked domains compared to generic measures.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

In this case study, a 46-year-old woman with tattoos and a history of hypothyroidism developed autoimmune-like symptoms, highlighting the importance of distinguishing ASIA syndrome from other immune disorders and assessing potential adjuvant exposure.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

In this study, combining ablative fractional microneedle radiofrequency with oral methylprednisolone was found to enhance hair density and mature hair rates in patients with alopecia areata better than oral methylprednisolone alone, though some adverse effects and increased hair shedding were noted over time.

This case report is the first to document the coexistence of bullous pemphigoid, malignant tumors, and alopecia areata in a patient, highlighting the complete resolution of skin lesions with dupilumab and spontaneous hair regrowth without disease-specific treatment.

This case report details a 47-year-old female with atopic dermatitis who developed alopecia areata after six months on dupilumab therapy; treatment discontinuation and other interventions led to complete hair regrowth, suggesting dupilumab may trigger alopecia areata in patients with atopic or autoimmune predispositions.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

In this study involving 20 participants with alopecia areata, microneedling was reported to clinically improve hair density and growth in affected areas, with results starting around one month and concluding three months after the final treatment session.